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Inﬂuenza, respiratory synctial virus, and parainﬂuenza are common respiratory infections in immunocompromised transplant
recipients, causing signiﬁcant morbidity and mortality in this patient population. This paper focuses on inﬂuenza and
parainﬂuenza virus infections in transplant patients with emphasis on the pandemic 2009 H1N1 inﬂuenza infection. Current
antiviral treatment recommendations for inﬂuenza and parainﬂuenza in immunocompromised patients as well as novel
investigational therapeutic approaches currently being testedinthe clinic are discussed. Inaddition tothe morbidity andmortality
caused by these viruses, the development of multidrug resistance leading to transmission of resistant viruses is of great public
health concern. The development of eﬀective new therapies for inﬂuenza and parainﬂuenza in these high-risk patients is needed
with randomized placebo-controlled studies to assess their clinical utility.
1.Introduction
Preventing and treating infectious diseases in immunocom-
promised patients presents special challenges, as current
treatments and vaccines may have limited eﬃcacy in this
population. Immune suppression is an essential component
of successful solid organ and hematopoietic cell transplan-
tation (SOT and HCT, resp.). SOT and HCT transplant
recipients require immune suppressants during the ﬁrst
100 days posttransplant period (e.g., FK506, cyclosporine,
prednisone) in order to prevent graft rejection and minimize
graft-versus-host disease (GVHD). SOT patients require
immunosuppression indeﬁnitely. Recipients of HCT and
SOT, undergo ablation of the immune system prior to
transplantation, and immune reconstitution occurs only
after successful engraftment of the transplant. Therefore,
SOT and HCT patients are severely immunocompromised
for a signiﬁcant period and are at high-risk for various
opportunistic infections that can cause signiﬁcant morbidity
and mortality.
Inﬂuenza (IFV), respiratory synctial virus (RSV), and
parainﬂuenza (PIV) are common respiratory infections in
both immune competent and immunocompromised popu-
lations. This paper will focus on inﬂuenza and parainﬂeunza
virus infections in transplant populations. The recent emer-
gence of the novel 2009 H1N1 (2009H1N1v) inﬂuenza virus
has illustrated many challenges in preventing and treating
respiratory viral infections and underscores the need for
appropriate combative therapies for this at risk population.
Some of these challenges include the lack of population
immunity to a novel IFV strain that led to pandemic
outbreaksaswellasthepotentialforthedevelopmentofdrug
resistance that has rendered existing therapeutic modalities
less eﬀective [1, 2]. Our search strategy for this paper
included the National Library of Medicine (PubMed) and
manufacturers trial data bases available on the internet.
While sharing similarities, infections caused by IFV
and PIV diﬀer in a number of important ways, noted in
Table 1. IFV and PIV are genetically distinct, single-stranded
RNA viruses of the Orthomyxoviridae and Paramyxoviri-
dae families, respectively. Both are tropic for the human
respiratory tract and utilize sialic acid as their receptors
[3–5]. While inﬂuenza is usually a seasonal disease, parain-
ﬂuenza occurs throughout the year [6]. Vaccination is an2 Advances in Virology
Table 1: Similarities and diﬀerences between IFV and PIV infections in the immunocompromised host.
Signiﬁcant
morbidity
and mortality
RNA
virus
Respiratory
receptor
Peak
incidence
Vaccination during
posttransplant period Antivirals Antiviral
resistance
Inﬂuenza Yes Yes Sialic acids Seasonal Yes (reduced eﬃcacy) Yes (unproven eﬃcacy) Yes
Parainﬂuenza Yes Yes Sialic acids Perennial None licensed No N/A
important and eﬀective approach to preventing inﬂuenza in
the immunocompetent host. However, eﬃcacy of vaccines is
generally reduced in HCT patients, particularly during the
ﬁrst 100 days post transplant, due to iatrogenic immune
suppression [7]. A recent report noted that only 51% of
HCT patients receiving inﬂuenza vaccine had adequately
protective antibody titers of 1:40 or higher after vaccination
[8]. In addition, a review of over 40 studies of SOT noted
ar e d u c t i o ni ne ﬃcacy of inﬂuenza vaccination in this
population compared to healthy controls [9]. Antivirals are
available to treat inﬂuenza infections but eﬃcacy has not
been deﬁnitively demonstrated in the transplant recipients.
Even with current antiviral therapy, IFV infections in
transplant recipients are characterized by prolonged viral
shedding leading to the risk of developing drug resistant
strains. PIV is even more problematic as there are neither
antiviral drugs nor vaccines available to treat or prevent this
infection.
2. Inﬂuenza Virus Infection in
the Immunocompromised Host
Inﬂuenza is typically caused by infection with either
inﬂuenza A virus (IFV A) or inﬂuenza B virus (IFV B)
each composed of 11 genes encoded by 8 negative-stranded
RNA segments enclosed in a lipid envelope derived from
the host cell. The envelope displays three key viral proteins:
hemagglutinin (HA) attaches the virus to host cell receptors
and mediates fusion of viral and cellular membranes;
neuraminidase (NA) facilitates release of new viruses from
the host cell, and M2 proteins serve as ion channels. Only
inﬂuenza A (IFVA) viruses are further classiﬁed by subtype
on the basis of the two main surface glycoproteins HA and
NA. There are 16 known HA subtypes and 9 known NA
subtypes of IFV A. Subtypes of inﬂuenza A that are currently
circulating worldwide include 2009H1N1v, seasonal H1N1
and H3N2v. Approved antiviral drugs target two of the
three above described viral proteins, M2 and NA. They
include the M2 inhibitors adamantanes (amantadine and
rimantadine), and the NA inhibitors (NAI) oseltamivir
(Tamiﬂu), peramivir, and zanamivir (Relenza).
The impact of seasonal inﬂuenza on immunocompro-
mised individuals has been clinically characterized primarily
through case studies. Complications from inﬂuenza in this
population include high rates of mortality, a need for
mechanical ventilation, progression to lower airway disease,
high rates of secondary bacterial infection, and persistent
viral shedding [10, 11]. Morbidity and mortality from
inﬂuenza is higher in immunocompromised individuals
compared to immunocompetent patients [10]. Lymphope-
nia appears to be an important risk factor for developing
lower airway disease such as pneumonia and mortality after
p r o g r e s s i o nt op n e u m o n i ac a nb ea sh i g ha s3 0 %[ 10].
There are multiple causes for the increased susceptibility
to inﬂuenza infection in immunocompromised patients.
In HCT, the intensity of myeloablation and consequent
lymphopenia,increasesusceptibilitytorespiratoryinfections
includinginﬂuenza[12].IFVintheimmunocompetentindi-
vidual usually results in viral shedding that is self-limited,
lasting ﬁve to six days. In contrast, viral shedding prolonged
for over 2 weeks is common in immunocompromised hosts
and has reportedly lasted as long as six months [13, 14].
Prolonged viral replication and shedding of IFV has been
associated with selection of resistant virus. For example, in a
small series of HCT subjects, the incidence of NAI resistance
was 67% [15]. Additional studies suggest that the incidence
ofresistanceishigherinimmunocompromisedpatientsthan
in immunocompetent adults or children [16, 17].
3. 2009H1N1v Infection
Emergence of the pandemic 2009H1N1v unveiled many
of the challenges in preventing and treating respiratory
viral infections. The 2009H1N1v originated from genetic
reassortment between IFVs from humans, birds, and pigs.
Both of the FDA-approved adamantanes lost inhibitory
activity towards the M2 channel of 2009H1N1v, due to
mutation in amino acid Ser31 [18, 19]. The M gene encoded
by this new pandemic inﬂuenza virus is reportedly similar
to the M gene in the Eurasian Swine virus, which confers
resistance to both amantadine and rimantidine. Fortunately,
the majority of 2009H1N1v isolates tested to date do remain
sensitive to the NAIs. However, inﬂuenza drug resistance to
2009H1N1v has been described in the immunocompetent
host. As of August 2010, the World Health Organization had
documented 304 cases associated with the H274Y mutations
(histidine to tyrosine at codon 274 in N2 nomenclature
or H275Y in N1 nomenclature) in H1N1v with reduced
sensitivity to oseltamivir [20, 21]. The concern for the
potential for increased resistance is also exempliﬁed by
a recent report of several genetic changes in 2009H1N1v
isolates from the Southern Hemisphere that have been
associated with vaccine breakthroughs and a number of
fatalities in both Singapore and Australia [22]. Thus there
is concern that drug resistance could become prevalent, as
occurred with previous seasonal IFV strains in 2009, when
mutations associated with resistance to oseltamivir were
found in almost all isolates [23].Advances in Virology 3
Many case reports available have documented signiﬁcant
morbidity and mortality in transplant patients infected in
2009H1N1v, and underscores the need to monitor the emer-
gence of new pandemic strains as well as the development of
viral resistance in these particular patient populations.
A number of cases of severe 2009H1N1v infection re-
sulting in signiﬁcant morbidity and mortality have been
d e s c r i b e di nH C Ta n dS O Tp a t i e n t sa n di ns o m et h e yw e r e
associated with drug resistance. A recent report of 237 cases
of 2009H1N1v in SOT and found that thirty-two percent
had pneumonia [24]. Sixteen percent were admitted to
intensive care and four percent died. Most patients received
oseltamivir and there was some clinical resolution from early
treatment with antivirals.
Another study examined the outcome of 27 H1N1v
patients postHCT [25]. Inﬂuenza-related 30-day overall
mortalitywas22%whilepatientswithlowerrespiratorytract
infection (LRTI) had a 43% mortality rate. Chronic steroid
use (≥20mg/day of prednisone equivalent) at the time of
presentation was a risk factor for LRTI and death.
Possibleriskfactorsandpooreroutcomeswereexamined
in13patientswith2009H1N1vinfectionpostHCT[26].Five
of 13 patients had 2009H1N1 inﬂuenza-induced LRTI and
only 1 survived. The authors noted that lower respiratory
tract disease and poorer outcomes occurred in patients
receiving intense immunosuppressive therapy who were
neutropenic and had GVHD.
Ant´ on et al. described the development of drug resis-
tance and the associated viral kinetics after infection with
2009H1N1v in an immunocompromised patient [27]. Resis-
tance to oseltamivir was observed after 10 days of treatment.
During subsequent treatment with zanamivir, viral loads
remained elevated for 5 days but then declined over an
additional 7 days.
The Centers for Disease Control (CDC) described infec-
tions in two immunocompromised individuals early in the
2009H1N1v pandemic [28]. The ﬁrst patient developed
inﬂuenza-like symptoms approximately 30 days after HCT,
and was treated with oseltamivir for >6 weeks, with evidence
of persistence infection by PCR assay. Sequence analysis
revealed variants containing H274Y mutation within two
weeks after beginning oseltamivir treatment began. A second
patient developed respiratory symptoms after two cycles of
chemotherapy and was initially treated with oseltamivir and
rimantadine. H274Y was detected and oseltamivir discontin-
ued. Treatment with inhaled zanamivir was attempted but
poorly tolerated. The patient was subsequently treated with
intravenous zanamivir and ribavirin in combination. She
remained symptomatic at the time of the report with no
additional followup on the patient’s clinical status.
Memmoli et al. described two HCT patients who rapidly
developed resistance to oseltamivir and peramivir after
infection with 2009H1N1v [29]. One developed respiratory
symptoms and was treated for 30 days with oseltamivir.
The H274Y mutation was detected by day 9 posttreatment.
The other developed mild upper respiratory symptoms and
was treated with oseltamavir. After 24 days of continuous
oseltamivirtherapythepatientdevelopedrespiratorydistress
and bronchoscopy revealed the presence of IFV. The patient
thenreceived10daysofinhaledzanamivirwithsymptomatic
improvement.
Selection of multidrug resistance to all available NAI’s
(oseltamivir, zanamivir, and peramivir) was described in a
pediatric patient who developed inﬂuenza-like symptoms
just prior to HCT [30]. Inﬂuenza was conﬁrmed by PCR
and the patient was treated with oseltamivir. Twelve days
later the H274Y mutation was detected and the patient
received zanamivir intravenously. The viral load decreased
and the patient was discharged but returned approximately
3 weeks later with upper respiratory symptoms. Intra-
venouszanamivirwasreinitiated,howevertheviruspersisted
and a new mutation, I223R, was detected on day 55,
exhibiting decreased sensitivity to oseltamivir, zanamivir,
and peramivir. Respiratory status of this patient worsened,
eventually leading to death.
Renuad et al., described a patient who developed res-
piratory symptoms and fever approximately 2 years after
allogeneic HCT [31]. The patient received oseltamivir, but
his respiratory status declined and bronchoalveolar lavage
ﬂuid revealed a high viral load for 2009H1N1v. PCR revealed
that >90% of viral RNA was wild-type, encoding histidine
at position 274. On day 7 the patient began intravenous
peramivir. However, on day 17, because of continued viral
shedding,peramivirwasdiscontinuedandH274Yconﬁrmed
as present by PCR, illustrating the emergence of resistance to
NAI’s during therapy.
Redelman-Sidi and colleagues characterized 45 cancer
and HCT patients with 2009H1N1v [32]. They responded
well to oseltamivir and had mild respiratory symptoms.
However, no patient in this cohort was less than 5 months
post transplantation. The most susceptible time for both
infection and prolonged shedding appears to be within the
ﬁrst 100 days after transplantation due to immunosuppres-
sion.
A recent troubling report described the ﬁrst docu-
mented person to person transmission of oseltamivir-
resistant 2009H1N1v in an inpatient stem-cell transplant
unit [33]. Eleven patients were infected with 2009H1N1v,
ten strains of which were genetically related. Eight of the ten
displayed the identical H274Y mutation.
4. Treatment Options for Inﬂuenza Infection in
t h eI m m un eC o m p r o m is edH o s t
Limited data exists from randomized controlled trials on the
utility and correct duration of use of licensed antivirals in
immunocompromised individuals.
5.NeuraminidaseInhibitors
At present, the predominant class of antiviral used for
the treatment and prophylaxis of inﬂuenza are the neu-
raminidase inhibitors (NAIs) which interfere with the
release of IFV particles from infected cells, preventing
the spread of infection to other cells. The licensed NAI’s
include oseltamivir, inhaled zanamivir, and recently under
Emergency Use Authorization, IV peramivir. IV zanamivir4 Advances in Virology
had been available through an Investigational New Drug
Application with the U.S. FDA [34].
The antiviral treatment options for immunocompro-
mised patients are empiric and tailored to the particu-
lar strain and its known sensitivity. As discussed above,
immunocompromised patients infected with IFV can have
prolonged infections lasting for more than ﬁve days [35].
Thus longer duration NAI treatment is usually required as
cessation of shedding is the desired primary outcome. The
speciﬁc duration of treatment is often empiric. While NAI’s
are well tolerated, postlicensing reports have indicated that
zanamivir may cause cough, bronchospasm, or even death
in patients with preexisting pulmonary disease. Hence, this
antiviral is should be used with caution in patients with
serious underlying respiratory diseases [36].
Oseltamivir is recommended for infection caused by
2009H1N1v in the immunocompetent host, as this virus
is typically resistant to the adamantanes [37], in contrast
to the previous 2008-2009 seasonal H1N1 strain, which
was characterized by oseltamivir resistance but susceptible
to amantadine [38]. As the development of resistance is
more complex in immunosuppressed individuals, the U.S.
Centers for Disease Control (CDC) has recommended that
patients with suspected or conﬁrmed oseltamavir resistant
2009H1N1v be treated with zanamivir [39]. If inhaled
zanamivir is contraindicated or not well tolerated, then IV
zanamivir is be available for compassionate use from its
manufacturer via an emergency IND application to the FDA.
The CDC also recommends that patients infected with IFV
suspected or documented to have H274Y mutation should
not be treated with peramivir. As clinical isolates expressing
the oseltamivir resistance-associated substitution H274Y
demonstrate reduced peramivir susceptibility in vitro. Of
note, a recent report examining IFV isolates from 2008–2010
found 28 resistant to both the adamantanes and oseltamivir
[40]. The emergence of dual resistant virus is obviously of
great public health concern.
The optimal therapy for severely immunosuppressed
patients with oseltamivir-resistant 2009H1N1v has not been
clearly deﬁned. Some severely immunosuppressed patients
with 2009H1N1v have been treated with a combination of
IV zanamivir and aerosolized ribavirin [41] or IV zanamivir
monotherapy No controlled studies however have conﬁrmed
the eﬃcacy of this combination approach [42]. A study
of 541 patients with conﬁrmed IFV investigated the use
of combination therapy (zanamivir and oseltamivir) versus
either oseltamivir or zanamivir monotherapy [43]. For
the primary endpoints of declining viral load and time
to alleviation of symptoms, combination therapy was less
eﬀective than oseltamivir monotherapy and not signiﬁcantly
more eﬀective than zanamivir monotherapy.
6. ClinicalInvestigationalTreatmentsfor
Inﬂuenza Other Than NAI’s
Favipiravir (T705, Toyama Chemical) is an investigational
antiviral drug that functions as a nucleotide analog and
inhibitor of viral RNA polymerase (PB1, PB2, and PA) [44,
45]. Preclinical studies by Itoh and colleagues suggest that
favipiravir is active against pandemic H1N1 strains both in
vitro and in vivo [46].
Arecentstudydemonstratedthatfavipiravirwaseﬀective
against oseltamivir-resistant seasonal and pandemic-viruses
in vitro [47]. In addition, the drug has potent activity against
H5N1 IFV in vivo [48]. Favipiravir, alone or in combination
with licensed NAIs, is being investigated in Phase II clinical
studies for the treatment of inﬂuenza. There are currently
no reports of the use of favipiravir in immunocompromised
patients.
DAS181 (Fludase, NexBio Inc.) is a recombinant fusion
protein with sialidase activity and carrying a cationic
sequence tag on the C-terminus [49]. This drug selectively
cleaves sialic acids from host cells, rendering them inaccessi-
ble to IFV, which seeks sialic acid as its receptor.
DAS181 has activity against numerous seasonal IFV
strains in vitro and in vivo as well as highly pathogenic avian
inﬂuenza strains (H5N1) [50] and against the 2009H1N1v
pandemicstrainsinvitro,invivo,andexvivo[51].Italsohas
antiviral activity against clinical IFV isolates with the H274Y
mutation [52]. DAS181 is currently in phase 2 trials for the
treatment of inﬂuenza in immunocompetent subjects.
7. Parainﬂuenza
Human PIVs account for a high proportion of pediatric
respiratory infections, including upper respiratory tract
infection (URTI), laryngotracheobronchitis (croup), bron-
chiolitis, and pneumonia [53]. Human PIVs are divided
into 4 types, with infections from types 1 and 3 accounting
for most disease. Human PIV is the major cause of croup
(type 1 is most frequent, followed by type 3 and type 2).
Of the PIV’s PIV3 is the most common pathogen. Acute
respiratory infections cause up to 18% of all admissions to
pediatric hospitals, and PIV can be detected in 9 to 30%
[54]. There are more than 5 million lower respiratory tract
infections in children younger than 5 years each year in the
United States, and PIV is found in as many as one-third
of them [55, 56]. Each year in the United States, between
500,000 to 800,000 cases of respiratory infection in persons
younger than 18 years result in hospitalizations, of which
approximately 12% display PIV infection [57]. Although
in the immunocompetent host, mortality from PIV is rare,
the mortality rate in immunocompromised patients is much
higher.
PIV is among the respiratory viruses most common
in the transplant population. Clinical presentation in the
immunocompromised population often diﬀers from that
of other respiratory viruses, such as respiratory synctial
virus (RSV). In one study, patients with PIV-3 presented
with upper respiratory tract infections (URI’s) or were
asymptomatic [58], contrasting with other respiratory infec-
tionswhichtypicallypresentsymptomatically.Recentstudies
document that PIV infections can occur in up to 18% of
HCT patients during the ﬁrst 100 days, and progress from
URI to pneumonia in 18 to 44% of patients [59]. These
reports suggest that PIV is more common than RSV or IFV
and is a signiﬁcant cause of mortality and morbidity in the
transplant population. Death from PIV in HCT can occurAdvances in Virology 5
in 25 to 45% of infected patients within 30 days after the
diagnosis of lower respiratory tract disease. In contrast to
IFV, PIV infections occur all year in HCT [60, 61]. PIV
infection also occurs following SOT. It has been suggested
that PIV infection causes signiﬁcant morbidity and may
be a major factor contributing to the poor prognosis of
lung transplant recipients [62]. In a large study, 5.3% of
lung transplant recipients were diagnosed with PIV infection
using bronchoalveolar lavage or transbronchial biopsy [63].
Lower respiratory tract involvement was reported to occur in
10 to 66% of infected patients. Although the time to devel-
opment of complications from respiratory viral infections
post lung transplantation is variable, most PIV infections
are described in the ﬁrst year. Up to 10% of lung transplant
patients develop acute respiratory failure requiring mechan-
ical ventilation following documented PIV infection [64].
DeathfollowingthedevelopmentofPIVinducedpneumonia
occurred in approximately 35% of patients receiving allo-
grafts following myeloablative conditioning [63]. Outbreaks
of parainﬂuenza infection in transplant centers can result
in signiﬁcant mortality due transmission to other patients.
A recent described outbreak of PIV-3 in 13 HCT patients
resulted in the death of 5 (38.5%), with all having lower tract
disease and 4 unsuccessfully treated with ribavarin [65].
8. Treatment Options for PIV Infection in
the Immunocompromised Host
Treatment or prevention options for patients with PIV are
limited as there are no approved antivirals or vaccines.
Ribavirin has shown both in vitro and in vivo activity against
PIV [66]. There have been numerous case reports of the use
of this drug against PIV in transplant patients. In one study,
only two of ﬁve PIV infections after HCT improved with oral
ribavirin [67, 68]. Reduction in mortality with aerosolized
Ribavirin, with or without immunoglobulin therapy (IVIG),
wasobservedinHCTtransplantpatientswithPIV-3induced
pneumonia [69]. In a cohort of 7 subjects with PIV post
lung or heart-lung transplant, a combination approach was
used utilizing ribavarin, corticosteroids, and intravenous
immunoglobulin G [69]. This study suggested that the use
of triple therapy resulted in slower declines in lung function
(FEV1), compared to historical controls.
9. ClinicalInvestigationalTreatmentsfor PIV
As PIV also uses sialic acids as receptors [70], the host
directed approach of DAS181, is being investigated for
activity against this pathogen. DAS181 eﬀectively inhibits
PIV in multiple cell lines, models of the human airway
epithelium, and in vivo animal models [71].
A recent report described a 64-year-old female post HCT
for acute myeloid leukemia (AML) developed progressive
PIV-3 infection documented by direct ﬂuorescent antibody
test (DFA) and accompanied by worsening pulmonary
status requiring supplemental oxygen [72]. The patient
demonstratedPIV-3sheddingforapproximately6weeksand
was treated with DAS181 for three days. Three days after the
last dose of treatment, respiratory symptoms and pulmonary
function improved and the patient’s nasal swab became
negativebyDFA.PCRofthenasalswabsrevealedanovertwo
log drop in virus levels. In-vitro inhibition of the patient’s
virus by DAS181 was also demonstrated. This patient’s lung
status improved without requiring supplemental oxygen.
However,thispatientpassedaway12dayslaterduetorelapse
of AML.
A live attenuated PIV-3 vaccine has been tested in
children and adults and was found to be safe but was found
to be nonimmunogenic in individuals who were seropositive
prior to immunization [73, 74]. However, this approach has
not yet been tested in immunocompromised patients where
vaccine induced antibody responses may be suboptimal
compared to immuncompetent individuals.
10. Conclusions
An area of great unmet medical need is the treatment of
respiratory viral infections in immunocompromised hosts.
During the ﬁrst month post transplantation, vaccinations
appear to be limited in their ability to prevent IFV and no
vaccine exists for PIV. For IFV, although eﬀective antivirals
exist to treat infections in the immunocompetent host,
their utility in this high-risk population is poorly deﬁned
and dependent on the susceptibility of the virus. The
rate of drug resistance selection appears to be higher in
immunocompromised patients than in the immune compe-
tent population and the transmission of multidrug resistant
virus remains a major public health concern. In the case of
PIV, no eﬀective treatment modalities are currently available.
Immunocompromised patients exemplify the most severe
complications associated with these respiratory infections.
New eﬀective therapies for IFV and PIV in these high-risk
patients remains an important public health priority.
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